The FTSE 100 index ended up 52.01 points, 0.6%, at 8,173.02. It is up 5.7% for the year. It is the best year for the blue-chip index since 2021, when it jumped 14% on a post-Covid recovery. In 2022, ...

Inspirit has not proposed an annual dividend, unchanged from the previous year, and the cash shell's agreed value was reported between GBP600,000 and GBP750,000.

Chair Eric Sanderson said the sale of EMIC-1 is a "key milestone for progressing the wind-down of the company". The deal can allow the firm to "further deleverage its balance sheet" by trimming the ...

(Alliance News) - ValiRx PLC on Tuesday said it has extended the exclusivity period for a proposed sub-license agreement with TheoremRx Inc for its VAL201 therapeutic candidate, setting a final ...

The company amended its half-year results following an independent audit required in support of the listing proposal. Loan notes announced on July 1 are now considered part of the firm's liability, it ...

Shares in Walls & Futures REIT are quoted at 12.50 pence and last traded at 15.00 pence on December 16 on the Aquis Exchange. Comments and questions to [email protected] ...

(Sharecast News) - UK stocks are expected to fall again on Tuesday, taking their lead from a sell-off on Wall Street overnight and a weak performance on Asian indices, with very little corporate or ...

London's flagship index is up 5.0% heading into the final day of 2024, falling short of loftier gains seen in US stocks this year, and the DAX 40 index in mainland Europe. Frankfurt's blue-chip ...

GSTechnologies Ltd, up 7.3% at 2.74 pence, 12-month range 0.55p-2.85p. Shares in the technology company hit this 12-month high as the year concludes. The firm, which operates businesses in the ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.

(Sharecast News) - UK stocks closed slightly lower in subdued trading on Monday, with market activity reflecting the final full session of 2024 amid a lack of significant corporate news or economic ...

RTW Biotech added that last Monday, Corxel said it acquired worldwide rights to an oral small molecule glucagon-like peptide-1 receptor agonist known as CX11 from Suzhou, China-based Vincentage Pharma ...